

NASDAQ Co. Working Towards Advanced Treatments for Parkinson's Disease and Cancer. Inhibikase Therapeutics (NASDAQ: IKT)

NASDAQ Company Diligently Working Towards Advanced Treatments for Parkinson's Disease and Cancer: Inhibikase Therapeutics, Inc. (Stock Symbol: IKT)

ATLANTA, GEORGIA, UNITED STATES,
June 7, 2021 /EINPresswire.com/ --

NASDAQ Company Diligently Working

Towards Advanced Treatments for Parkinson's Disease and Cancer: [Inhibikase Therapeutics, Inc.](https://www.inhibikase.com/) (Stock Symbol: IKT)



“

The acceleration of our Phase 1 study for IKT-148009 should allow us to move into evaluation of the safety, tolerability & pharmacokinetics in Parkinson's patients early in the third quarter of 2021.”

*Milton Werner, Ph.D.,
President and Chief Executive
Officer of IKT*

IKT is Currently Performing Phase I Clinical Trials

□ NASDAQ Listed Clinical-Stage Pharmaceutical Company.

□ Focus on Development of Effective Therapeutics for Parkinson's and Related Neurodegeneration Disorders as well as Certain Cancers.

□ \$20.4 Million in Grant Funding Plus \$19 Million in Investor Capital.

□ Phase I Trials for Proprietary Therapy Drug on Accelerated Plan.

□ Experienced Management, Consultants, Board of Directors and Nearly All KOLs in the Field on Scientific Advisory Board.

Experienced Management, Consultants, Board of Directors and Nearly All KOLs in the Field on Scientific Advisory Board.

Inhibikase Therapeutics, Inc. ([NASDAQ: IKT](#)) is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. The IKT multi-therapeutic pipeline focuses on neurodegeneration and its lead program for IKT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, intends to treat Parkinson's disease inside and outside the brain.

IKT is currently performing its Phase I, randomized single ascending dose and multiple ascending dose study to determine the safety, tolerability and pharmacokinetics of IKT-148009 in older and healthy subjects. IKT is also advancing a novel drug delivery platform to treat certain forms of cancer at the same time as it is developing novel drugs for the treatment of neurodegenerative disease. IKT is headquartered in Atlanta, Georgia with offices in Boston, Massachusetts.

IKT is Driving Functional Reversal of Parkinson's Disease

□ Multi-therapeutic pipeline with emphasis on neurodegeneration inside and outside of the brain.

□ Our lead inhibitor of the Abelson

Tyrosine Kinase (c-Abl), IKT-148009, halts and reverses functional loss in animal models that recreate progressive human disease.

□ Five clinical programs in neurodegeneration and one clinical program in oncology by close of 2021.

□ Ongoing Phase 1 trial with IKT-148009 reaches therapeutic drug exposures seen in animal models at just 25 mg oral dose 1x/day in humans.

□ Multiple patent families for lead compound with expiration of 2036 and beyond

□ \$20.4 million in grants and contracts from NIH, DoD, the Michael J. Fox Foundation, and the Georgia Research Alliance, all peer-reviewed

□ \$19 million in investor capital since 2018.



\$IKT Therapeutics

IKT-148009 ONGOING TRIALS IN SAFETY AND DOSING\

Low Toxicity, Brain Penetrant c-Abl Inhibitor in Clinical Development

| NOVEL ABL KINASE INHIBITOR | RELATIVE POTENCY | 14-Day Toxicology in Rat/Monkey ¹ Human equivalent dose of 600 mg |
|----------------------------|------------------|---|
| 148019 | 8 | Cardiovascular: None |
| 148003 | 12 | Renal: None |
| 148027 | 17 | Liver: None |
| 148032 | 23 | Bone marrow: None |
| 148009 | 18* | Spleen: None |
| 01427 | 36 | Blood: None |
| Imatinib | 1 | PBMCs: Slight increase in neutrophils within normal limits |
| | | Cytotoxicity: None in primary or mature cells |
| | | Sustainable brain concentration: > 1 micromolar |

¹Ongoing chronic toxicology studies in rat and monkey have completed 13 weeks

IKT-148009

- No observed toxicity from off target kinase inhibition
- No CNS toxicity
- No toxicity observed even on 210+ day dosing in mice at >150 mg/kg/day
- Nearly complete neuroprotection in α -synuclein progressive disease models
- Multi-kilogram clinical batch production completed, 6 step synthesis

*Compositions of matter patent protection through 2036

\$IKT Highlights

Management Team with Deep Experience in Drug Development and Commercialization

Executive

Milton Werner, PhD President & CEO

Previously, Dr. Werner served as Director of Research at Celltaxys. From September 1996 until June 2007, Dr. Werner was a Head of the Laboratory of Molecular Biophysics at The Rockefeller University in New York City. Throughout his scientific career, Dr. Werner has been an innovator integrating chemistry, physics, and biology into a comprehensive approach to solving problems in medicine. Dr. Werner is the author or co-author of more than 70 research articles, reviews, and book chapters and has given lectures on his research work throughout the world.

Joseph Frattaroli, CPA Chief Financial Officer

Mr. Frattaroli is a certified public accountant with more than 15 years of experience in public company filings and compliance for Nasdaq and OTC Markets companies. Previously, he provided chief financial officer and consulting services for several emerging biopharmaceutical and medical device companies, with responsibilities that included capital formation, deal structuring, and assisting private companies in their transition to becoming publicly traded SEC registrants.

C. Warren Olanow, MD, Interim Chief Medical Officer and Chief Executive Officer of CLINTREX

Dr. Olanow is the former Henry P. and Georgette Goldschmidt Professor and Chairman of the Department of Neurology at the Mount Sinai School of Medicine. Prior to joining Mount Sinai, he served on the faculties of McGill University, Duke University, and the University of South Florida. He is the former President of the Movement Disorder Society, past President of the International Society of Motor Disturbances, and former Treasurer of the American Neurological Association. He has served on the executive committee of the Michael J. Fox Foundation Scientific Advisory Board, and he is the former Chairman of the Scientific Advisory Board of the Bachmann-Strauss Parkinson Foundation and of the Dystonia Foundation. Dr. Olanow is the former Co-Editor-in-Chief of the journal Movement Disorders. Dr. Olanow received his medical degree from the University of Toronto, performed his neurology training at the New York Neurological Institute at Columbia Presbyterian Medical Center at Columbia University, and undertook postgraduate studies in neuroanatomy at Columbia University and authored more than 600 articles in the field of neurodegeneration.



\$IKT Management

Highly experienced and respected management team, consultants, Board of Directors, and nearly all KOLs in the field on Scientific Advisory Board

First Quarter 2021 Highlights of Recent Activity

On May 17th IKT reported financial results for the first quarter ended March 31, 2021, and highlighted recent developments.

Board of Directors

Mr. Dennis Berman has been a co-founder, board member, and/or seed investor in many private biotechnology and technology companies, five of which have gone public. He currently serves as the President of Molino Ventures, LLC, a board advisory and venture capital firm and was co-founder and Executive Vice President of Corporate Development of Tocagen. Other public companies for which Mr. Berman has served as a seed investor, co-founder, and/or board member include Intervu (one of the first software-as-a-service companies), which was acquired by Akamai; Kintera, Inc. (an online fundraising pioneer), which was acquired by Blackboard; Gensia (focused on purine/pyrimidine metabolism compounds), which was acquired by Teva; and Vasgene (the first U.S. gene therapy company that utilized a non-replicating retrovirus), which was acquired by Chiron/Novartis. Mr. Berman also was a seed investor in Calabrian (a water treatment company), which was acquired by SK Capital.

Dr. Paul Grint, MD has more than two decades of experience in biologics and small-molecule research and development, including the successful approval and commercialization of products in the infectious diseases, immunology, and oncology therapeutic areas. He is on the Board of Amlynx Pharmaceuticals and Synedgen. He served on the Board of Cardia Bio, on the Board of Amlynx Pharmaceuticals, on the Board of Synedgen and was CEO and member of the Board of Directors of AmpliPhi Biosciences. Dr. Grint has also served in senior management roles at Cereba, Forest Laboratories, Kalypso, Pfizer, IDEC Pharmaceuticals, and Schering-Plough Corporation. He is a Fellow of the Royal College of Pathologists, and holds a bachelor's degree from St. Mary's Hospital College, University of London and a medical degree from St. Bartholomew's Hospital College, University of London.

Dr. Roy Freeman, MD is Professor of Neurology at the Harvard Medical School and Director of the Center for Autonomic and Peripheral Nerve Disorders in the Department of Neurology at Beth Israel Deaconess Medical Center in Boston, Massachusetts. Dr. Freeman is former chairman of the World Federation of Neurology research group on the autonomic nervous system, former President of the American Autonomic Society, and former chairman of the Autonomic Section of the American Academy of Neurology. Dr. Freeman is Editor-in-Chief of *Autonomic Neuroscience: Basic and Clinical* and on the editorial boards of *The Clinical Journal of Pain*, *Pain: Clinical Updates*, and *Clinical Autonomic Research*. He is a founder of several companies in pain and neurodegenerative disease and is on the scientific advisory boards of many large and small pharmaceutical and biotechnology companies.

Ms. Elizabeth O'Farrell recently retired from a 25-year career with Eli Lilly and Company, lastly serving as Chief Procurement Officer and Leader, Global Head of Shared Services from 2012 to 2017. Prior to that, she advanced through a number of executive management positions including Senior Vice President, Policy and Finance; Senior Vice President, Finance; Chief Financial Officer, Lilly USA; Chief Financial Officer, Lilly Canada; and General Auditor. Before joining Eli Lilly, Ms. O'Farrell currently serves on the board of PDX BioPharma, Genen Corporation where she is a member of the Audit Committee and member of the board of directors of Lensar and serves as member and chair of their Audit Committee. Ms. O'Farrell holds a BS in accounting with honors and an MBA in management information systems, both from Indiana University.

Industry-Leading Advisors

Robert Hauser, MD
Professor of Neurology, University of South Florida College of Medicine - Director USF Parkinson's Disease and Movement Disorders Center

Jeffrey Kordower, PhD
Alla V and Solomon Jeaner Professor of Aging & Neurological Sciences Rush University Medical Center

Dr. Ken Marek
President and Senior Scientist, Institute of Neurodegenerative Disorders

Dr. Ted Dawson, MD, PhD
Neurodegeneration and Stem Cell Programs, Institute for Cell Engineering, Departments of Neurology, Physiology, Pharmacology, and Molecular Sciences - The Johns Hopkins University School of Medicine

Dr. Valina Dawson, PhD
Neurodegeneration and Stem Cell Programs, Institute for Cell Engineering, Departments of Neurology and Physiology The Johns Hopkins University School of Medicine

Dr. Warren Olanow, MD, FRCP
Henry P. and Georgette Gottesman Professor and Chairman Emeritus, Mount Sinai School of Medicine

Dr. Karl Kiebertz, MD, MPH
Robert J. Joynt Professor in Neurology, Senior Associate Dean for Clinical Research, Director of the Clinical & Translational Science Institute, Founder Center for Human Experimental Therapeutics (CHET) - University of Rochester Medical Center Clinics, Inc.

Dr. Jay Parichha, MBBS, MD
Director, Johns Hopkins Center for Neurogastroenterology Professor of Medicine

\$IKT Board of Directors

Accelerated timelines for Phase 1 Study of IKT-148009 for the treatment of PD and associated GI Disorders: In February 2021 IKT commenced patient dosing in its Phase

1 study evaluating the safety, tolerability and pharmacokinetics of IKT-148009, the Company's novel brain penetrant Abelson tyrosine kinase (c-Abl) inhibitor with the potential to modify Parkinson's disease and its gastrointestinal complications. In April 2021, IKT announced that it had accelerated the timeline for completion of the study based on early data that provided the opportunity to seek regulatory approval to commence dosing of PD patients in the third quarter of 2021, much earlier than previously anticipated.

Advancing chronic toxicology studies of IKT-148009 to permit long-term dosing in patients: In January 2021 IKT initiated 3- and 6-month long-term toxicology studies of IKT-148009 in mice and 3- and 9-month long-term toxicology studies of IKT-148009 in primates as required to obtain regulatory approval for chronic administration of IKT-148009 in patients. IKT has completed 3-month toxicology studies and is presently completing its histopathology analysis in preparation for submission of the data for regulatory review early in the third quarter of 2021. IKT expects to complete 6- and 9-month toxicology studies in the fourth quarter of 2021.

Initiated clinical batch manufacturing and pill formulation of IKT-001Pro. In February, 2021, IKT initiated clinical batch manufacturing and final product formulation of IKT-001Pro, the IKT prodrug formulation of Imatinib, designed as a potentially safer, better tolerated treatment for Imatinib-sensitive cancers such as stable-phase Chronic Myeloid Leukemia (CML). IKT expects to file an Investigational New Drug (IND) application in the third quarter of 2021, with initiation of clinical development as soon as practicable after the filing, subject to FDA acceptance of the IND.

The acceleration of the Phase 1 study for its lead candidate, IKT-148009 should allow IKT to move into evaluation of the safety, tolerability and pharmacokinetics in Parkinson's patients early in the third quarter of 2021. Concurrently, IKT is advancing two long term toxicology studies in

animals, which will allow for chronic administration of IKT-148009 in patients following FDA review and acceptance.

In the third quarter of 2021, IKT plans to file its IND application for IKT-001Pro, which holds the potential to be a safer and better tolerated treatment for cancers such as CML and expects to initiate clinical development as soon as practicable following the submission of the IND application.

For more information on Inhibikase (ITK) visit: www.inhibikase.com

DISCLAIMER: FrontPageStocks/CorporateAds.com (CA) is a third-party publisher and news dissemination service provider. FPS/CA is NOT affiliated in any manner with any company mentioned herein. FPS/CA is news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FPS/CA's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. FPS/ CA is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. FPS/CA has been compensated \$500 by a third party for dissemination of this article.

Disclaimer/Safe Harbor:

These news releases and postings may contain forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

SOURCE: CorporateAds.com

IKT
Inhibikase Therapeutics, Inc.
+1 678-392-3419

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/542853315>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.